NIH funding opportunity announcements for COVID-19 research

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required): $3M per year for three years due January 21, 2021

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. See the full RFA here.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to Coronavirus Disease 2019 (COVID-19): Funding dependent on PA-20-135 due August 21, 2020

NIH is seeking applications from current NLM R01 awardees that can, in one or two years, enhance public health infrastructure for predicting and monitoring viral disease outbreaks. See the full RFA here.

 Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool: Funding dependent on PA-20-135 due September 1, 2020

The goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. See the full RFA here.

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed): $300,000 per year for two years; LOI due on August 21, 2020 and full application due September 15, 2020

This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. See the full RFA here.

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed): $2M per year for two years due September 15, 2020

The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of wastewater-based testing (WBT), to address topics such as: investigation and demonstration of specific approaches aiming to increase sensitivity and to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models. See the full RFA here.

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional): $500,000 per year for three years; LOI due August 30, 2020 and full application due September 30, 2020

This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. See the full RFA here.

Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed): $500,000 per year for two years due September 18, 2020

This FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings. See the full RFA here.

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed): $500,000 per year for two years due September 18, 2020

This FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. See the full RFA here.

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed): $4M per year for four years; LOI due August 31, 2020 and full application due September 30, 2020

This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. See the full RFA here.

Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional): $750,000 per year for three years due September 15, 2020

The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this FOA is to solicit applications to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. See the full RFA here.

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional): $500,000 per year for two years (R61 phase), $1M per year for two years (R33 phase); LOI due August 31, 2020 and full application due September 30, 2020

This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes. See the full RFA here.

Image source: 

Image caption: